-+ 0.00%
-+ 0.00%
-+ 0.00%
SAVARA: FDA's review of SAVARA's application for moxestine bioproduct licensing is ongoing; no revised date of action has been provided.
Share
Listen to the news
SAVARA: FDA's review of SAVARA's application for moxestine bioproduct licensing is ongoing; no revised date of action has been provided.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending